000			03743cam a2200421Mi 4500
001			ocn785777976
003			OCoLC
005			20240726105329.0
008			120227s2012 enka ob 001 0 eng d
040			_aE7B _beng _epn _erda _cE7B _dOCLCQ _dYDXCP _dCUS _dOCLCQ _dNT _dIDEBK _dCDX _dOCLCA _dOCLCF _dDEBSZ _dDA _dEBLCP _dUKDOC _dOCLCQ _dAGLDB _dOCLCQ _dSTF _dVTS _dREC _dAU@ _dOCLCQ _dLEAUB _dAJS _dDKU _dOCLCO
020			_a9781848166295 _q((electronic)l(electronic)ctronic)
050	0	4	_aQP519 _b.A585 2012
049			_aMAIN
245	1	0	_aAntibody drug discovery /Clive R. Wood, editor.
260			_aLondon : _bImperial College Press, _c(c)2012.
300			_a1 online resource (xv, 473 pages) : _billustrations (some color)
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_adata file _2rda
490	1		_aMolecular medicine and medicinal chemistry ; _vv. 4
504			_a2
505	0	0	_aCh. 1. Humanization of antibodies / _rOlivier Leger and Jose W. Saldanha -- _tchapter 2. Selection and screening of antibody phage display libraries / _rDavid R. Buckler [and others] -- _tchapter 3. Affinity maturation approaches for antibody lead optimization / _rDavid Lowe, Trevor Wilkinson and Tristan J. Vaughan -- _tchapter 4. Transgenic mice rearranging human antibodies / _rSean Stevens -- _tchapter 5. Isotype selection and Fc engineering: design and construction of fit-for-purpose therapeutic antibodies / _rWilliam R. Strohl -- _tchapter 6. Antibody expression from bacteria to transgenic animals / _rPaul Stephens and Berni M. Sweeney -- _tchapter 7. Current trends in antibody purification and lead selection / _rJie Chen and Andrew Nixon -- _tchapter 8. Design and application of immunoconjugates for cancer therapy / _rSherif El Sheikh [and others] -- _tchapter 9. Dual-targeting bispecific antibodies as new therapeutic modalities for cancer / _rZhenping Zhu -- _tchapter 10. Antibody fragments and alternate protein scaffolds / _rLioudmila Tchistiakova [and others.
520	0		_aMonoclonal antibodies have become important treatments for cancer, inflammation and a wide range of other diseases, representing an increasing share of the most successful pharmaceutical markets. The technologies to discover these drugs have been developed by select centers of excellence in industry and academia, and are continually being fine tuned in the race to identify the best antibody-based drug candidates and accelerate their paths to patients. The objective of this volume is to provide a series of guides to those evaluating and preparing to enter particular areas within the field and to offer specialized perspectives to established researchers. The chapters set into context the significance of key developments and important considerations for selecting different approaches, such as antibody humanization, isotype selection, lead candidate selection criteria and protein production. All contributors to this work are experts in their fields and many have played pivotal roles in the creation of these technologies.
530			_a2 _ub
650		0	_aImmunoenzyme technique.
650		0	_aAntibody-drug conjugates.
650		0	_aImmunology _xTechnique.
650		0	_aDrug development.
650		0	_aPharmaceutical biotechnology.
650		0	_aImmunoglobulins.
655		1	_aElectronic Books.
700	1		_aWood, Clive R.
856	4	0	_uhttps://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=516762&site=eds-live&custid=s3260518 _zClick to access digital title | log in using your CIU ID number and my.ciu.edu password
942			_cOB _D _eEB _hQP.. _m2012 _QOL _R _x _8NFIC _2LOC
994			_a92 _bNT
999			_c96801 _d96801
902			_a1 _bCynthia Snell _c1 _dCynthia Snell